189 related articles for article (PubMed ID: 26358312)
1. Different mutation profiles and clinical characteristics among Hispanic patients with non-small cell lung cancer could explain the "Hispanic paradox".
Arrieta O; Ramírez-Tirado LA; Báez-Saldaña R; Peña-Curiel O; Soca-Chafre G; Macedo-Perez EO
Lung Cancer; 2015 Nov; 90(2):161-6. PubMed ID: 26358312
[TBL] [Abstract][Full Text] [Related]
2. Clinical and pathological characteristics, outcome and mutational profiles regarding non-small-cell lung cancer related to wood-smoke exposure.
Arrieta O; Campos-Parra AD; Zuloaga C; Avilés A; Sánchez-Reyes R; Manríquez ME; Covián-Molina E; Martínez-Barrera L; Meneses A; Cardona A; Borbolla-Escoboza JR
J Thorac Oncol; 2012 Aug; 7(8):1228-34. PubMed ID: 22659961
[TBL] [Abstract][Full Text] [Related]
3. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
[TBL] [Abstract][Full Text] [Related]
4. Imaging Characteristics of Driver Mutations in EGFR, KRAS, and ALK among Treatment-Naïve Patients with Advanced Lung Adenocarcinoma.
Park J; Kobayashi Y; Urayama KY; Yamaura H; Yatabe Y; Hida T
PLoS One; 2016; 11(8):e0161081. PubMed ID: 27518729
[TBL] [Abstract][Full Text] [Related]
5. Molecular spectrum of somatic EGFR and KRAS gene mutations in non small cell lung carcinoma: determination of frequency, distribution pattern and identification of novel variations in Indian patients.
Das BR; Bhaumik S; Ahmad F; Mandsaurwala A; Satam H
Pathol Oncol Res; 2015 Jul; 21(3):675-87. PubMed ID: 25637496
[TBL] [Abstract][Full Text] [Related]
6. Molecular characterization of chronic obstructive pulmonary disease-related non-small cell lung cancer through aberrant methylation and alterations of EGFR signaling.
Suzuki M; Wada H; Yoshino M; Tian L; Shigematsu H; Suzuki H; Alaa M; Tamura H; Fujiwara T; Nagato K; Motohashi S; Moriya Y; Hoshino H; Yoshida S; Shibuya K; Hiroshima K; Nakatani Y; Yoshino I
Ann Surg Oncol; 2010 Mar; 17(3):878-88. PubMed ID: 19841986
[TBL] [Abstract][Full Text] [Related]
7. [EGFR and KRAS Gene Mutations in 754 Patients with Resectable Stage I-IIIa Non-small Cell Lung Cancer and Its Clinical Significance].
Zhao J; Gao J; Guo L; Hu X; Liu Q; Zhao J; Liu L; Jiang J; Wang M; Liang Z; Xu Y; Chen M; Zhang L; Li L; Zhong W
Zhongguo Fei Ai Za Zhi; 2017 Sep; 20(9):617-622. PubMed ID: 28935015
[TBL] [Abstract][Full Text] [Related]
8. Detection of epidermal growth factor receptor mutations in plasma by mutant-enriched PCR assay for prediction of the response to gefitinib in patients with non-small-cell lung cancer.
He C; Liu M; Zhou C; Zhang J; Ouyang M; Zhong N; Xu J
Int J Cancer; 2009 Nov; 125(10):2393-9. PubMed ID: 19530244
[TBL] [Abstract][Full Text] [Related]
9. Predictive and prognostic factors in second- and third-line erlotinib treatment in NSCLC patients with known status of the EGFR gene.
Krawczyk P; Kowalski DM; Krawczyk KW; Szczyrek M; Mlak R; Rolski A; Szudy A; Kieszko R; Winiarczyk K; Milanowski J; Krzakowski M
Oncol Rep; 2013 Sep; 30(3):1463-72. PubMed ID: 23783797
[TBL] [Abstract][Full Text] [Related]
10. Incidence of non-small-cell lung cancer among California Hispanics according to neighborhood socioeconomic status.
Wong ML; Clarke CA; Yang J; Hwang J; Hiatt RA; Wang S
J Thorac Oncol; 2013 Mar; 8(3):287-94. PubMed ID: 23399956
[TBL] [Abstract][Full Text] [Related]
11. Impact of epidermal growth factor receptor (EGFR) activating mutations and their targeted treatment in the prognosis of stage IV non-small cell lung cancer (NSCLC) patients harboring liver metastasis.
Castañón E; Rolfo C; Viñal D; López I; Fusco JP; Santisteban M; Martin P; Zubiri L; Echeveste JI; Gil-Bazo I
J Transl Med; 2015 Aug; 13():257. PubMed ID: 26248464
[TBL] [Abstract][Full Text] [Related]
12. Direct comparison of 3 PCR methods in detecting EGFR mutations in patients with advanced non-small-cell lung cancer.
Ikeda T; Nakamura Y; Yamaguchi H; Tomonaga N; Doi S; Nakatomi K; Iida T; Motoshima K; Mizoguchi K; Nagayasu T; Tsukamoto K; Kohno S
Clin Lung Cancer; 2012 Sep; 13(5):369-74. PubMed ID: 22410386
[TBL] [Abstract][Full Text] [Related]
13. High expression of dihydropyrimidine dehydrogenase in lung adenocarcinoma is associated with mutations in epidermal growth factor receptor: implications for the treatment of non--small-cell lung cancer using 5-fluorouracil.
Mochinaga K; Tsuchiya T; Nagasaki T; Arai J; Tominaga T; Yamasaki N; Matsumoto K; Miyazaki T; Nanashima A; Hayashi T; Tsukamoto K; Nagayasu T
Clin Lung Cancer; 2014 Mar; 15(2):136-144.e4. PubMed ID: 24405586
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy response in East Asian non-small cell lung cancer patients harboring wild-type or activating mutation of epidermal growth factor receptors.
Lin CC; Hsu HH; Sun CT; Shih JY; Lin ZZ; Yu CJ; Chen GG; Hsin MK; Lam KC; Leung L; Yang CH; Mok T
J Thorac Oncol; 2010 Sep; 5(9):1424-9. PubMed ID: 20631634
[TBL] [Abstract][Full Text] [Related]
15. [Detection and Analysis of EGFR and KRAS Mutations
in the Patients with Lung Squamous Cell Carcinomas].
Zhang H; Yang X; Qin N; Li X; Yang H; Nong J; Lv J; Wu Y; Zhang Q; Zhang X; Wang J; Su D; Zhang S
Zhongguo Fei Ai Za Zhi; 2015 Oct; 18(10):621-5. PubMed ID: 26483334
[TBL] [Abstract][Full Text] [Related]
16. Prospective cohort study of clinical characteristics and management patterns for patients with non-small-cell lung cancer in the Russian Federation: EPICLIN-Lung.
Tjulandin S; Imyanitov E; Moiseyenko V; Ponomarenko D; Gurina L; Koroleva I; Karaseva V
Curr Med Res Opin; 2015 Jun; 31(6):1117-27. PubMed ID: 25867537
[TBL] [Abstract][Full Text] [Related]
17. Frequency of EGFR mutations in non-small cell lung cancer patients: screening data from West Siberia.
Gervas P; Ivanova A; Vasiliev N; Ananina O; Zharkova O; Rogovieva O; Verzhbitskaya N; Didichuk I; Cheremisina O; Popova N; Goldberg V; Cherdyntsev E; Choynzonov E; Cherdyntseva N
Asian Pac J Cancer Prev; 2015; 16(2):689-92. PubMed ID: 25684509
[TBL] [Abstract][Full Text] [Related]
18. Genotyping non-small cell lung cancer (NSCLC) in Latin America.
Arrieta O; Cardona AF; Federico Bramuglia G; Gallo A; Campos-Parra AD; Serrano S; Castro M; Avilés A; Amorin E; Kirchuk R; Cuello M; Borbolla J; Riemersma O; Becerra H; Rosell R;
J Thorac Oncol; 2011 Nov; 6(11):1955-9. PubMed ID: 22005474
[TBL] [Abstract][Full Text] [Related]
19. Is there a specific phenotype associated with the different subtypes of KRAS mutations in patients with advanced non-small-cell lung cancers?
Dumenil C; Vieira T; Rouleau E; Antoine M; Duruisseaux M; Poulot V; Lacave R; Cadranel J; Massiani MA; Wislez M
Lung Cancer; 2015 Dec; 90(3):561-7. PubMed ID: 26520186
[TBL] [Abstract][Full Text] [Related]
20. Updated Frequency of EGFR and KRAS Mutations in NonSmall-Cell Lung Cancer in Latin America: The Latin-American Consortium for the Investigation of Lung Cancer (CLICaP).
Arrieta O; Cardona AF; Martín C; Más-López L; Corrales-Rodríguez L; Bramuglia G; Castillo-Fernandez O; Meyerson M; Amieva-Rivera E; Campos-Parra AD; Carranza H; Gómez de la Torre JC; Powazniak Y; Aldaco-Sarvide F; Vargas C; Trigo M; Magallanes-Maciel M; Otero J; Sánchez-Reyes R; Cuello M
J Thorac Oncol; 2015 May; 10(5):838-843. PubMed ID: 25634006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]